Tvardi Therapeutics, Inc. Share Price & Technical Analysis
TVRD · $3.44 (-3.64%)
Healthcare / Biotechnology
$3.44
-3.64%
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical de…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
6% return in May, -8% avg return in past 3 year May month.
-15% return in 2026, -59% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -7% | 3% | -20% | 3% | 6% | – | – | – | – | – | – | – | -15% |
| 25 | -17% | -5% | 8% | 67% | 14% | -23% | 12% | 15% | 30% | -88% | -11% | 5% | 7% |
| 24 | -24% | 54% | 8% | -17% | -14% | -62% | 28% | 3% | -9% | 0% | -3% | 70% | 34% |
| 23 | 6% | -13% | -52% | -14% | -24% | -12% | 17% | -22% | -35% | -22% | -26% | -23% | -219% |
| 22 | -6% | -11% | 18% | -29% | -5% | 9% | -3% | 16% | -9% | 0% | 23% | -9% | -4% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$37.71M
P/E ratio
—
52W high
$43.65
52W low
$2.75
Volume
55,381
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Tvardi Therapeutics, Inc. share price today?
- Tvardi Therapeutics, Inc. (TVRD) last traded around $3.44 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TVRD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TVRD. Download the app for real-time alerts.
- How can I analyze Tvardi Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.